From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

European Psychiatry : the Journal of the Association of European Psychiatrists
Christoph U Correll

Abstract

Determinants of antipsychotic selection and response include parameters of the primary disorder, psychiatric and physical comorbidities, past treatment effects, patient preferences, availability and acceptability of different treatments and formulations, as well as expected efficacy and safety. In the absence of consistent and sufficiently large efficacy differences among antipsychotics (except for clozapine in refractory patients), and in view of a greater focus on physical health, functional outcomes and quality of life, relatively more predictable differences in adverse events have become an important management consideration. Treatments are often selected because of a relatively lower propensity for extrapyramidal and sexual side effects, sedation, and, especially, the reduced development of cardiometabolic risk states and disorders. In this context, differences in receptor binding affinity, intrinsic activity and in the half life of antipsychotics are crucial to adopt adequate dosing and switching strategies. Dopamine rebound phenomena can occur when the level of dopamine blockade is not kept relatively constant during the switch process. This can happen when the new antipsychotic is underdosed or not fully absorbed, the s...Continue Reading

References

Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
May 3, 2005·The American Journal of Psychiatry·Nina SchoolerUNKNOWN Early Psychosis Global Working Group
Jun 14, 2005·Schizophrenia Research·Gary RemingtonBruce Christensen
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 6, 2005·Journal of Psychopharmacology·Peter J Weiden
Jan 13, 2006·The Journal of Clinical Psychiatry·Christoph U Correll
Jan 24, 2006·The Journal of Clinical Psychiatry·Christoph U Correll
Jan 12, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Wesley Sowers
May 8, 2007·Schizophrenia Bulletin·Thomas R E BarnesUNKNOWN UK Prescribing Observatory for Mental Health
Nov 7, 2007·CNS Spectrums·Christoph U Correll
Jan 5, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Christoph U Correll
Jun 3, 2008·Neuropsychobiology·David Fischer-BarnicolUNKNOWN Working Group 'Drugs in Psychiatry'
Aug 30, 2008·The International Journal of Neuropsychopharmacology·Konstantinos N Fountoulakis, Eduard Vieta
Aug 14, 2009·Expert Review of Neurotherapeutics·Keming GaoJoseph R Calabrese
Aug 19, 2009·The American Journal of Psychiatry·J Craig Nelson, George I Papakostas

❮ Previous
Next ❯

Citations

Feb 1, 2012·Molecular Psychiatry·T CohenF Levine
Dec 21, 2011·Journal of Psychiatry & Neuroscience : JPN·Johnny SuRic M Procyshyn
Jul 10, 2014·Journal of Clinical Psychopharmacology·Mahyar EtminanJames M Brophy
Mar 1, 2012·Journal of Clinical Psychopharmacology·Jimmi NielsenDavid Taylor
Apr 29, 2015·Expert Review of Clinical Pharmacology·Mathias Zink, Christoph U Correll
Feb 13, 2015·Expert Opinion on Pharmacotherapy·Andrea FagioliniGiuseppe Maina
Jan 15, 2015·Current Medical Research and Opinion·Arash RaoufiniaFrank Larsen
Aug 15, 2013·Psychiatry and Clinical Neurosciences·Davy VancampfortMichel Probst
Feb 24, 2012·Acta Psychiatrica Scandinavica·R E NielsenJ Nielsen
May 25, 2016·The Psychiatric Clinics of North America·Donna AmesLynn M Yudofsky
Jan 1, 2015·Nature Reviews. Disease Primers·René S KahnThomas R Insel
Jun 4, 2014·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Debra L FoleyCherrie A Galletly
Jun 5, 2015·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Christoph U CorrellMarc De Hert
Aug 2, 2011·Expert Opinion on Pharmacotherapy·Fernando CañasJosé Manuel Montes
Sep 23, 2014·Expert Opinion on Emerging Drugs·Luisa-Sophie KösterChristoph U Correll
May 9, 2012·Expert Opinion on Drug Safety·Juan A GallegoChristoph U Correll
Mar 10, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andrea MurruEduard Vieta
Feb 5, 2011·Postgraduate Medicine·Alessandro RossiChristoph U Correll
Mar 19, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jiamei LianChao Deng
Apr 20, 2016·Journal of Child and Adolescent Psychopharmacology·Zainab Al-DhaherMaren Carbon
Apr 26, 2016·Issues in Mental Health Nursing·Irma H MahoneDiane E Snow
Apr 5, 2016·Expert Review of Neurotherapeutics·Robert E Davis, Christoph U Correll
Sep 10, 2013·Child and Adolescent Psychiatric Clinics of North America·Harvey N Kranzler, Sarah D Cohen
Aug 30, 2012·The Psychiatric Clinics of North America·Christoph U Correll, Juan A Gallego

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here